Effect of adjuvant on pharmacokinetics, organ distribution and humoral immunity of hepatitis B surface antigen after intramuscular injection to rats

Archives of Pharmacal Research

Volumn 35, Issue 9, 2012, Pages 1621-1628

  Jeong, Eun Ju ^a   Maeng, Han Joo ^b   Lee, Hyo Jong ^b   Kim, Yeonjeong ^b   Kim, Chong Kook ^b,c  

^a Korea Institute of Toxicology   (South Korea)

^b Inje University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Aluminium phosphate (AP); Hepatitis B surface antigen (HBsAg); Humoral immunity; Immunoadjuvant; Lymphatic uptake; Organ distribution; Pharmacokinetics

Indexed keywords

ALUMINUM PHOSPHATE; FORMALDEHYDE; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; IODINE 125;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG LIVER LEVEL; HUMORAL IMMUNITY; LYMPH NODE; MALE; NONHUMAN; ORGAN DISTRIBUTION; RADIOACTIVITY; RAT; SEROCONVERSION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; FIXATIVES; FORMALDEHYDE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HOT TEMPERATURE; IMMUNITY, HUMORAL; INJECTIONS, INTRAMUSCULAR; IODINE RADIOISOTOPES; LIVER; LYMPH NODES; MALE; PHOSPHATES; RANDOM ALLOCATION; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; VACCINATION;

EID: 84872114088     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0913-1     Document Type: Article

References (25)

1. Bourquin, C., Anz, D., Zwiorek, K., Lanz, A. L., Fuchs, S., Weigel, S., Wurzenberger, C., von der Borch, P., Golic, M., Moder, S., Winter, G., Coester, C., and Endres, S., Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol., 181, 2990-2998 (2008).
2. De Temmerman, M. L., Rejman, J., Demeester, J., Irvine, D. J., Gander, B., and De Smedt, S. C., Particulate vaccine: on the quest for optimal delivery and immune response. Drug Discov. Today, 16, 569-582 (2011).
3. Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., Larocque, D., Van Mechelen, M., and Garçon, N., AS04, an aluminum salt- and TLR4 agonistbased adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol., 183, 6186-6197 (2009).
4. Eickhoff, T. C. and Myers, M., Workshop summary, Aluminium in vaccines. Vaccine, 20, S1- S4 (2002).
5. Gonzalez, M. L., Usandizaga, M., Alomar, P., Salv', F., Martin, F., Erroz, M. J., and Lardinois, R., Intradermal and intramu- scular route for vaccination against hepatitis B. Vaccine, 8, 402-406 (1990).
6. Gupta, P. K. and Hung, C. T., Quantitative evaluation of targeted drug delivery systems, Int. J. Pharm., 56, 217- 226 (1989).
7. Harlow, E. and Lane, D., Antibodies; a laboratory manual, Cold Spring Harbor Laboratory, New York, pp. 118-119, 324-329, (1988).
8. Henriksen-Lacey, M., Korsholm, K. S., Andersen, P., Perrie, Y., and Christensen, D., Liposomal vaccine delivery systems. Expert Opin. Drug Deliv., 8, 505-519 (2011).
9. HogenEsch, H., Mechanisms of stimulation of the immune response by aluminium adjuvants. Vaccine, 20, S34-S39 (2002).
10. Kim, C.-K. and Jeong, E. J., Development of dried liposomes as effective immune-adjuvant for hepatitis B surface antigen. Int. J. Pharm., 115, 193-199 (1995).
11. Kim, C.-K. and Jeong, E. J., Enhanced lymph node delivery and immunogenicity of hepatitis B surface antigen incorporated in galactosylated liposomes. Int. J. Pharm., 147, 143-151 (1997).
12. Kim, C.-K., Hwang, S. J, and Lee, M. G., The organ targetability of small and large albumin microspheres containing free and HSA conjugated methotrexate. Int. J. Pharm., 89, 91-102 (1993).
13. Kim, C.-K., Jeong, E. J., and Kim, M.-H., Comparison of in vivo fate and immunogenicity of hepatitis surface antigen incorporated in cationic and neutral liposomes. J. Microencapsul., 17, 297-306 (2000).
14. McKee, A. S., MacLeod, M. K., Kappler, J. W., and Marrack, P., Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol., 8, 37 (2010).
15. Munks, M. W., McKee, A. S., Macleod, M. K., Powell, R. L., Degen, J. L., Reisdorph, N. A., Kappler, J. W., and Marrack, P., Aluminium adjuvants elicit fibrin-dependent extracellular traps in vivo. Blood, 116, 5191-5199 (2010).
16. O'Hagan, D. T. and De Gregorio, E., The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov. Today, 14, 541-551 (2009).
17. Pandey, R. S. and Dixit, V. K., Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J. Drug Target., 18, 282-291 (2010).
18. Perrie, Y., Mohammed, A. R., Kirby, D. J., McNeil, S. E., and Bramwell, V. W., Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm., 364, 272-280 (2008).
19. Ravizzini, G., Turkbey, B., Barrett, T., Kobayashi, H., and Choyke, P. L., Nanoparticles in sentinel lymph node mapping. Nanomed. Nanobiotechnol., 1, 610-623 (2009).
20. Saini, V., Jain, V., Sudheesh, M. S., Jaganathan, K. S., Murthy, P. K., and Kohli, D. V., Comparison of humoral and cellmediated immune responses to cationic PLGA microspheres containing recombinants hepatitis B antigen. Int. J. Pharm., 408, 50-57 (2011).
21. Schüttler, C. G., Wend, U. C., Faupel, F. M., Lelie, P. N., and Gerlich W. H., Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). J. Clin. Virol., 47, 238-242 (2010).
22. Segura, E. and Villadangos J. A., Antigen presentation by dendritic cells in vivo. Curr. Opin. Immunol., 21, 105-110 (2009).
23. Sun, H. X., Xie, Y., and Ye, Y. P., ISCOMs and ISCOMATRIX. Vaccine, 27 4388-4401 (2009).
24. Tabor, E., Buynak, E., Smallwood, L. A., Snoy, P., Hilleman, M., and Gerety, R. J., Interaction of hepatitis B virus by three methods: treatment with pepsin, urea, or formalin. J. Med. Virol., 11, 1-9 (1983).
25. von Andrian, U. H. and Mempel, T. R., Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol., 3, 867-878 (2003).